The Centers for Disease Control (CDC) stated today (28th) that the domestic COVID-19 epidemic continues to rise and has entered the epidemic period.
In addition, it coincides with the summer vacation travel peak season, which increases the risk of disease transmission.
The CDC calls on the public to take precautions such as washing hands frequently, wearing masks, and getting vaccinated.
When entering and leaving medical care institutions, in crowded places where it is not possible to maintain an appropriate distance or in poorly ventilated places, or when in close contact with the elderly or people with weakened immune systems, it is recommended to wear masks.
If you have a fever or respiratory symptoms, it is recommended to stay at home as much as possible and avoid unnecessary outings.
People with severe risk factors should seek medical attention as soon as possible if they have suspected symptoms so that doctors can diagnose and treat them early and prescribe antiviral drugs to reduce the risk of complications or death after infection.
According to data from the Taiwan Centers for Disease Control (CDC), the COVID-19 epidemic in Taiwan is on the rise.
In the 29th week (July 19-25), there were 10,605 outpatient and emergency room visits related to COVID-19, a 117.4% increase compared to the previous week (July 12-18).
Last week (July 21-27), there were 42 new locally transmitted severe cases and 2 new locally transmitted deaths.
Since October 2025, there have been a cumulative total of 203 locally transmitted cases of COVID-19 complicated by severe illness, with 25 deaths.
The majority of severe cases are among those aged 65 and above (73.4%) and those with a history of chronic diseases (83.7%).
90.6% of these cases have not received the COVID-19 vaccine this season.
In the past four weeks, the most prevalent local variant strain has been NB.1.8.1.
Clinical manifestations are mainly upper respiratory symptoms, including sore throat, cough, nasal congestion, runny nose, fever, fatigue, headache, and muscle aches.
The global positivity rate has recently risen, with all regions except Southeast Asia and Africa showing an upward trend; neighboring countries/regions such as China, Hong Kong, Japan, and the United States are also experiencing an increase in cases.
Currently, the predominant circulating variant globally is NB.1.8.1 (58.76%), followed by XFG (19.07%) and JN.1 (15.46%).
The Taiwan Centers for Disease Control (CDC) indicated that as of July 26, 2026, approximately 1.742 million COVID-19 vaccinations have been administered this season, with vaccination rates for those aged 65 and above at 21.01% for the first dose and 0.56% for the second dose.
Data shows that severe cases in Taiwan are still predominantly among those aged 65 and above and those with a history of chronic diseases, and over 90% of these individuals have not received the COVID-19 vaccine this season.
Considering the escalating COVID-19 situation in Taiwan and the recent upward trend in the global positivity rate, the government has extended the expanded government-funded COVID-19 vaccination program until September 28, 2026.
Domestic COVID-19 vaccine stocks are sufficient, with 437,000 doses remaining (including approximately 435,000 doses of Moderna vaccine and approximately 2,000 doses of Novavax vaccine).
The Novavax vaccine expires on July 31st of this year. Those who have not yet received this season's COVID-19 vaccine are urged to get vaccinated as soon as possible. Furthermore, three high-risk groups—those aged 65 and above, indigenous people aged 55 and above, and those with compromised immune systems—are advised to receive their second dose as soon as possible if they have already received one dose and the interval is 6 months (180 days) to further enhance their protection and effectively reduce the risk of severe illness or death.
The Centers for Disease Control (CDC) stated that in response to the recent surge in COVID-19 cases, it has comprehensively reviewed and consolidated domestic medical supplies. There are still 168,000 doses of the publicly funded oral antiviral drug Paxlovid and 17,000 doses of Xocova. There are also 153,000 doses of injectable Remdesivir in stock.
For information on COVID-19 vaccination sites, contracted hospitals for publicly funded oral antiviral drugs, and the latest epidemic prevention policies, please visit the CDC's website (https://www.cdc.gov.tw) under the "COVID-19 Prevention Zone" or call the toll-free epidemic prevention hotline 1922 (or 0800-001922).
In addition, approximately 630,000 home rapid COVID-19 test kits are available to meet the public's needs. Information can be found on the Food and Drug Administration's "Home COVID-19 Test Kit Supply Information Zone" (https://reurl.cc/XxWbbM), or by visiting pharmacies, convenience stores, or other sales channels.
Source:
Link: https://www.cdc.gov.tw/Bulletin/Detail/HqTIUKC58EK9fO9AVWU3Cg?typeid=9
____
No comments:
Post a Comment